Beacon eye gene therapy hits mark in late-stage study

Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.  

By Gwendolyn Wu • Sept. 21, 2026

Xenon shares fall following depression trial pause

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

By Jonathan Gardner • Sept. 18, 2026

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

Skyhawk racks up more support for Huntington’s drug

The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.

By Jacob Bell • Sept. 16, 2026

WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight

The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

By Ben Fidler , Jonathan Gardner • Sept. 15, 2026

Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.

By Jonathan Gardner • Sept. 14, 2026

AstraZeneca’s newly approved pill fails frontline breast cancer study

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year. 

By Delilah Alvarado • Sept. 14, 2026

Tyra disappoints investors with bladder cancer data

Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

By Jonathan Gardner • Sept. 9, 2026

Novartis RNA drug falls short in rare muscle disease study

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

By Jacob Bell • Sept. 8, 2026

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.

By Ben Fidler • Sept. 5, 2026

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

By Jonathan Gardner • Sept. 4, 2026

Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.

By Kristin Jensen • Sept. 3, 2026

Akeso, Summit cancer drug confirms lung cancer survival benefit

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

By Jonathan Gardner • Sept. 3, 2026

Novartis says MS pill succeeds in two large studies

Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.

By Delilah Alvarado • Sept. 1, 2026

Alumis’ TYK2 drug fails in key lupus study

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis. 

By Gwendolyn Wu • Sept. 1, 2026

ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.

By Ben Fidler • Aug. 31, 2026

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

By Jonathan Gardner • Aug. 28, 2026

New data could widen use of AstraZeneca, Amgen immune disease drug

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

By Delilah Alvarado • Aug. 27, 2026

Spyre tumbles as immune drug misses mark in rheumatoid arthritis

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.

By Delilah Alvarado • Aug. 26, 2026

[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

By BioPharma Dive's studioID • Aug. 24, 2026

Cancer vaccine win restores Wall Street’s faith in Moderna

Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet. 

By Delilah Alvarado , Ben Fidler • Aug. 20, 2026

Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.

By Jonathan Gardner • Aug. 19, 2026

AstraZeneca scores in lung cancer; Sandoz inks a China deal

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

By BioPharma Dive staff • Aug. 18, 2026

Amylyx’s bet on a GLP-1 blocker pays off

A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.

By Jacob Bell • Aug. 18, 2026

Argenx jumps on Phase 3 data for blockbuster Vyvgart

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments. 

By Delilah Alvarado • Aug. 17, 2026

EyePoint plummets on pivotal data for main drug

Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.

By Jacob Bell • Aug. 17, 2026